Stockreport

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. - Ordinary Shares  (ENLV) 
PDF Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy [Read more]